Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.06.19
Views: 782
Rating:

Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany

Prof Michael Geißler talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the final results from the phase II randomised VOLFI trial which compared mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 non-resectable mCRC patients.

He explains that two cohorts were specified: patients judged as definitely unresectable and patients with a chance if a secondary resection.

Prof Geißler reports that the primary endpoint was met and that the response rate increased from 66% with FOLFOXIRI to 86.7 with mFOLFOXIRI and panitumumab.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation